Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05775198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 21, 2025 (before its estimated March 13, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revisedv3
  2. Start date changed from estimate of Mar 13, 2023 to Mar 1, 2023v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test the effect of modulated specialised immune cells isolated from the patients' own blood when administered to the uterus before embryo transfer on the IVF outcome (implantation, pregnancy and live birth rates). To achieve this, blood will be obtained from eligible participants. Target cells will be isolated and incubated with the tested modulator for 24h, and returned to the uterine cavity 1 day prior to embryo transfer. Researchers will compare the reproductive outcome of the tested intervention to that of a control group who will not receive the investigated cell treatment prior to embryo transfer.
Trial Details
NCT Number NCT05775198
Lead Sponsor Nadezhda Women's Health Hospital
Conditions
(from sponsor)		 Infertility, Female, IVF
Related terms Infertility, Female
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov